OncoSec’s TAVO potential in TNBC depends on administration operability and impact on metastases

OncoSec
TAVO is a plasmid-based interleukin (IL)-12 to be administered locally at the tumor site using OncoSec’s electroporation device. Credit: Ed Uthman.